Sign In
Share

Lenacapavir (Sunlenca)

All References

Filter by Category
  • All References
  • Clinical Studies
    • Treatment-Naive
    • Treatment-Experienced
    • Switch/Simplification
    • Dual Therapy
    • Monotherapy
    • PREP
    • PEP
    • Acute HIV
  • Resistance/Virological Failure
  • Pharmacology
    • General Pharmacology
    • Adverse Effects
    • Drug Interactions
  • Pregnancy/Women
  • Pediatrics
  • Review
  • Bester SM, Adu-Ampratwum D, Annamalai AS, et al. Structural and Mechanistic Bases of Viral Resistance to HIV-1 Capsid Inhibitor Lenacapavir. mBio. 2022;13:e0180422.
    [PubMed Abstract]
  • Cilento ME, Ong YT, Tedbury PR, Sarafianos SG. Drug Interactions in Lenacapavir-Based Long-Acting Antiviral Combinations. Viruses. 2022;14:(6):1202.
    [PubMed Abstract]
  • Dvory-Sobol H, Shaik N, Callebaut C, Rhee MS. Lenacapavir: a first-in-class HIV-1 capsid inhibitor. Curr Opin HIV AIDS. 2022;17:15-21.
    [PubMed Abstract]
  • Gupta SK, Berhe M, Crofoot G, et al. Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial. Lancet HIV. 2023;10:e15-e23.
    [PubMed Abstract]
  • Margot N, Ram R, Rhee M, Callebaut C. Absence of Lenacapavir (GS-6207) Phenotypic Resistance in HIV Gag Cleavage Site Mutants and in Isolates with Resistance to Existing Drug Classes. Antimicrob Agents Chemother. 2021;65(3):e02057-20.
    [PubMed Abstract]
  • Margot N, Vanderveen L, Naik V, et al. Phenotypic resistance to lenacapavir and monotherapy efficacy in a proof-of-concept clinical study. J Antimicrob Chemother. 2022;77:989-95.
    [PubMed Abstract]
  • Margot NA, Naik V, VanderVeen L, et al. Resistance Analyses in Highly Treatment-Experienced People With Human Immunodeficiency Virus (HIV) Treated With the Novel Capsid HIV Inhibitor Lenacapavir. J Infect Dis. 2022;226:1985-91.
    [PubMed Abstract]
  • Nka AD, Bouba Y, Teto G, et al. Evaluation of HIV-1 capsid genetic variability and lenacapavir (GS-6207) drug resistance-associated mutations according to viral clades among drug-naive individuals. J Antimicrob Chemother. 2022;78:272-5.
    [PubMed Abstract]
  • Orkin C. Lenacapavir in first-line therapy. Lancet HIV. 2023;10:e2-e3.
    [PubMed Abstract]
  • Segal-Maurer S, DeJesus E, Stellbrink HJ, et al. Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection. N Engl J Med. 2022;386:1793-1803.
    [PubMed Abstract]

Share by e-mail

Since you've received 80% or better on this quiz, you may claim continuing education credit.

You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.